108 related articles for article (PubMed ID: 36077308)
1. Characterization of Vemurafenib-Resistant Melanoma Cell Lines Reveals Novel Hallmarks of Targeted Therapy Resistance.
Radić M; Vlašić I; Jazvinšćak Jembrek M; Horvat A; Tadijan A; Sabol M; Dužević M; Herak Bosnar M; Slade N
Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36077308
[TBL] [Abstract][Full Text] [Related]
2. Quantitative Proteomics Links the Intermediate Filament Nestin to Resistance to Targeted BRAF Inhibition in Melanoma Cells.
Schmitt M; Sinnberg T; Nalpas NC; Maass A; Schittek B; Macek B
Mol Cell Proteomics; 2019 Jun; 18(6):1096-1109. PubMed ID: 30890564
[TBL] [Abstract][Full Text] [Related]
3. CHMFL-BMX-078, a BMX inhibitor, overcomes the resistance of melanoma to vemurafenib via inhibiting AKT pathway.
Jiang S; Jiang T; Huang H; Chen X; Li L; Wang Z; Fei J; Liu C; Liu Z; Cheng Y
Chem Biol Interact; 2022 Jan; 351():109747. PubMed ID: 34813779
[TBL] [Abstract][Full Text] [Related]
4. Silencing FOXP2 reverses vemurafenib resistance in BRAF
Jiang S; Huang Y; Li Y; Gu Q; Jiang C; Tao X; Sun J
Endocrine; 2023 Jan; 79(1):86-97. PubMed ID: 36331719
[TBL] [Abstract][Full Text] [Related]
5. MitoCur-1 induces ferroptosis to reverse vemurafenib resistance in melanoma through inhibition of USP14.
Li G; Zhou C; Wang L; Zheng Y; Zhou B; Li G; Ma Z; Sun P; Deng Y; Su L; Wang J; Cui H
Pigment Cell Melanoma Res; 2024 Mar; 37(2):316-328. PubMed ID: 37985430
[TBL] [Abstract][Full Text] [Related]
6. Evodiamine inhibits growth of vemurafenib drug-resistant melanoma via suppressing IRS4/PI3K/AKT signaling pathway.
Guo X; Huang S; Zhang Y; Wang H; Li L; Ran J; Chen D; Li X; Li J
J Nat Med; 2024 Mar; 78(2):342-354. PubMed ID: 38324123
[TBL] [Abstract][Full Text] [Related]
7. Protein kinase C inhibitor anchored BRD4 PROTAC PEGylated nanoliposomes for the treatment of vemurafenib-resistant melanoma.
Fu Y; Rathod D; Patel K
Exp Cell Res; 2020 Nov; 396(1):112275. PubMed ID: 32898554
[TBL] [Abstract][Full Text] [Related]
8. Oral lipid nanocomplex of BRD4 PROteolysis TArgeting Chimera and vemurafenib for drug-resistant malignant melanoma.
Saraswat A; Vartak R; Hegazy R; Fu Y; Rao TJR; Billack B; Patel K
Biomed Pharmacother; 2023 Dec; 168():115754. PubMed ID: 37871557
[TBL] [Abstract][Full Text] [Related]
9. Cold atmospheric plasma sensitizes melanoma cells to targeted therapy agents in vitro.
Yan C; Zhao L; Zhang X; Chu Z; Zhou T; Zhang Y; Geng S; Guo K
J Biophotonics; 2024 Mar; 17(3):e202300356. PubMed ID: 38041219
[TBL] [Abstract][Full Text] [Related]
10. PEG-peptide hydrogels reveal differential effects of matrix microenvironmental cues on melanoma drug sensitivity.
Tokuda EY; Jones CE; Anseth KS
Integr Biol (Camb); 2017 Jan; 9(1):76-87. PubMed ID: 28001152
[TBL] [Abstract][Full Text] [Related]
11. Development and in-depth characterization of BRAFi-resistant melanoma cell lines in vitro and in vivo.
Saraswat A; Patel K
Exp Cell Res; 2024 Apr; 438(1):114033. PubMed ID: 38593916
[TBL] [Abstract][Full Text] [Related]
12. Sox10-Deficient Drug-Resistant Melanoma Cells Are Refractory to Oncolytic RNA Viruses.
Abou-Hamad J; Hodgins JJ; Yakubovich E; Vanderhyden BC; Ardolino M; Sabourin LA
Cells; 2023 Dec; 13(1):. PubMed ID: 38201278
[TBL] [Abstract][Full Text] [Related]
13. Disrupting cellular memory to overcome drug resistance.
Harmange G; Hueros RAR; Schaff DL; Emert B; Saint-Antoine M; Kim LC; Niu Z; Nellore S; Fane ME; Alicea GM; Weeraratna AT; Simon MC; Singh A; Shaffer SM
Nat Commun; 2023 Nov; 14(1):7130. PubMed ID: 37932277
[TBL] [Abstract][Full Text] [Related]
14. Kisspeptin-mediated improvement of sensitivity to BRAF inhibitors in vemurafenib-resistant melanoma cells.
Guzzetti C; Corno C; Vergani E; Mirra L; Ciusani E; Rodolfo M; Perego P; Beretta GL
Front Oncol; 2023; 13():1182853. PubMed ID: 37790750
[TBL] [Abstract][Full Text] [Related]
15. Ezrin Inhibition Overcomes Acquired Resistance to Vemurafenib in BRAFV600E-Mutated Colon Cancer and Melanoma Cells In Vitro.
Car I; Dittmann A; Vasieva O; Bočkor L; Grbčić P; Piteša N; Klobučar M; Kraljević Pavelić S; Sedić M
Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37629086
[TBL] [Abstract][Full Text] [Related]
16. Vemurafenib induces a noncanonical senescence-associated secretory phenotype in melanoma cells which promotes vemurafenib resistance.
Peng J; Lin Z; Chen W; Ruan J; Deng F; Yao L; Rao M; Xiong X; Xu S; Zhang X; Liu X; Sun X
Heliyon; 2023 Jul; 9(7):e17714. PubMed ID: 37456058
[TBL] [Abstract][Full Text] [Related]
17. Trametinib-Resistant Melanoma Cells Displaying MITF
Koziej P; Kluszczynska K; Hartman ML; Czyz M
Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175614
[TBL] [Abstract][Full Text] [Related]
18. Fractionation and Characterization of Triterpenoids from
Vilkickyte G; Petrikaite V; Marksa M; Ivanauskas L; Jakstas V; Raudone L
Antioxidants (Basel); 2023 Feb; 12(2):. PubMed ID: 36830023
[TBL] [Abstract][Full Text] [Related]
19. Survival Mechanisms of Metastatic Melanoma Cells: The Link between Glucocorticoids and the Nrf2-Dependent Antioxidant Defense System.
Obrador E; Salvador-Palmer R; López-Blanch R; Oriol-Caballo M; Moreno-Murciano P; Estrela JM
Cells; 2023 Jan; 12(3):. PubMed ID: 36766760
[TBL] [Abstract][Full Text] [Related]
20. p53 Family in Resistance to Targeted Therapy of Melanoma.
Vlašić I; Horvat A; Tadijan A; Slade N
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]